NCT06263491View on ClinicalTrials.gov

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

March 1, 2027

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Rituximab

Given by PO

DRUG

Pirtobrutinib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER